Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an announcement.
Clarity Pharmaceuticals Ltd announced a change in the interest of its director, Colin David Biggin, involving the acquisition of 592,373 fully paid ordinary shares and the disposal of 1,000,000 options. This transaction, executed through the exercise of options on a cashless basis, reflects a strategic move by the director, potentially impacting the company’s stock dynamics and signaling confidence in the company’s future prospects.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd operates within the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment and diagnosis of serious diseases, particularly in oncology.
Average Trading Volume: 3,013,122
Technical Sentiment Signal: Sell
Current Market Cap: A$873.1M
See more insights into CU6 stock on TipRanks’ Stock Analysis page.